One phase I study evaluated the side effects and optimal dose of entinostat and nivolumab (anti-PD-1 mAb) when given together with ipilimumab (anti-CTLA-4) in treating patients with unresectable or metastatic HER2-negative BC (NCT02453620). This evidence concerns the gene CTLA4 and breast cancer.